Immuno-Oncology 360° Agenda 2026 Page

Claire Thuning-Roberson, PhD, CEO, AbBC Therapies

Showing Events in 1 Track from 09:25am to 10:05am

Grand Opening of the IO360° Networking Café

9:25AM - 10:05AM

Grand Opening of the IO360° Networking Café

Showing Events in 1 Track from 10:05am to 10:45am

New Technologies in Transformational Biology (Continued)

10:05AM - 10:25AM

AstraZeneca’s Bet on In Vivo CAR-T: A Preclinical Perspective

Mark Cobbold, PhD, SVP IO and Cell Therapy Discover, AstraZeneca

10:25AM - 10:45AM

Antisense Oligonucleotides (ASOs) for Cancer: Why This Modality’s Moment Has Arrived

Zdravka Medarova, PhD, CSO & Co-founder, TransCode Therapeutics

Showing Events in 1 Track from 11:00am to 11:10am

10 Min Health Break

11:00AM - 11:10AM

10 Min Health Break

Showing Events in 1 Track from 11:10am to 12:20pm

Morning Tracks

11:10AM - 12:20PM

Two Track Choices: IO Novel Technologies Showcase

Participating Companies:

Showing Events in 2 Tracks from 12:20pm to 01:35pm

Lunch and Networking

Lunch & 1:1 Partnering Meetings Begin

Women's Luncheon

3rd Annual Women Leaders in IO Panel & Luncheon

Moderator:

Marisa Dolled-Filhart, PhD, Global Team Lead, Early Oncology; Asset and Portfolio Management, Daiichi Sankyo US

Theresa LaVallee, PhD, Chief Scientific & Development Officer, Coherus Oncology

Showing Events in 2 Tracks from 01:40pm to 03:20pm

TRACK 1: New Tech in Transformational Biology

Next-Generation Cancer Vaccines: Mining the Dark Genome for Novel Shared Antigens

Jon Moore, PhD, CSO, Epitopea

2:00PM - 2:20PM

Cytokine-Based ADCs: IL-12 and IL-18 as Immune-Modulating Payloads

2:35PM - 2:55PM

Engineering Bispecific Antibodies: Preclinical Design and Construction

2:55PM - 3:15PM

Pharma/Academia Case Study

TRACK 2: Imaging-Driven Innovation in IO

The Imaging Reality Check: Practical Insights from a Leading IO Trialist

Diwakar Davar, MD, Associate Professor, Clinical Director, Melanoma and Skin Cancer Program, UPMC Hillman Cancer Center

2:00PM - 2:40PM

Panel: Imaging Lessons from IO 1.0 to Shape IO 2.0: From Smarter Design to Meaningful Impact

David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo

2:40PM - 3:20PM

Panel: Measuring What Matters: Using Biomarkers to Guide Patient Selection and Treatment in IO

Greg Goldmacher, MD, PhD, MBA, Associate VP, Clinical Research; Head, Clinical Imaging & Pathology, Merck Research Laboratories

Catherine Hines, PhD, Executive Director and Head, Clinical Imaging, GSK

Dejan Knezevic, PhD, Senior Director, Pharma Partnerships, Natera

Showing Events in 1 Track from 03:25pm to 04:05pm

Afternoon Networking Break

3:25PM - 4:05PM

Afternoon Networking Break and Partnering Meetings

Showing Events in 2 Tracks from 04:10pm to 05:40pm

TRACK 1: Breakthroughs in Translational Science Part 1

What Drives an Effective Anti-Tumor Immune Response? Insights from Blood-Borne and Solid Tumors

Erik Manting, PhD, CEO, Mendus

4:45PM - 5:05PM

Targeting IL-27 to Activate Antitumor Immunity: Insights from Casdozokitug

Sruthi Ravindranathan, PhD, Senior Scientist, Translational Medicine, Coherus Oncology

5:20PM - 5:40PM

New Translational Insights from the VG161 Oncolytic Virotherapy Study

William Jia, PhD, CSO & Co-founder, Virogin Biotech

TRACK 2: Imaging-Driven Innovation in IO

Understanding, Detecting and Harnessing Immunogenic Cell Death in IO

Lorenzo Galluzzi, PhD, Associate Professor Cancer Signaling and Microenvironment Research Program, Fox Chase Cancer Center, Temple Health

4:30PM - 5:10PM

Panel - From Hype to Impact: Where AI in Imaging Is Moving the Needle in IO Development

Greg Goldmacher, MD, PhD, MBA, Associate VP, Clinical Research; Head, Clinical Imaging & Pathology, Merck Research Laboratories

Diederik Grootendorst, PhD, Director, Global Oncology Imaging, Bristol Myers Squibb

Petr Jordan, PhD, CTO, Onc.AI

Jayant Narang, MD, Sr Medical Director, Clinical Oncology Imaging Lead, Preclinical and Translational Sciences, Takeda Pharmaceuticals

5:10PM - 5:40PM

Improving Tumor Assessment Using Growth Dynamics

Speakers:

Susan E. Bates, Professor of Medicine / Director, Translational Cancer Medicine, Columbia University Medical Center

Antonio "Tito" Fojo, MD, Professor of Medicine / Co-Director, Columbia Adrenal Surgery Center, Columbia University Medical Center

Showing Events in 1 Track from 05:50pm to 06:50pm

12th Annual Networking Reception

5:50PM - 6:50PM

12th Annual Networking Reception & 1:1 Partnering Meetings

Showing Events in 1 Track from 07:30am to 08:10am

Registration & Morning Remarks

7:30AM - 8:00AM

Registration

8:00AM - 8:10AM

IO360° Opening Remarks

Showing Events in 1 Track from 08:15am to 09:05am

Opening Keynote

8:15AM - 8:25AM

Presenting the IO360° Lifetime Achievement Award

8:25AM - 8:50AM

Keynote: Checkpoint Blockade and Beyond: Charting the Next Era of Immuno-Oncology

Keynote Speaker:

Jedd Wolchok, MD, PhD, Meyer Director of the Sandra and Edward Meyer Cancer Center and Professor of Medicine, Weill Cornell Medicine

8:50AM - 9:05AM

Immunotherapy Through the Eyes of Patient and Physician

Fireside Guests:

Brendan Connors, Patient, Advocate

Jedd Wolchok, MD, PhD, Meyer Director of the Sandra and Edward Meyer Cancer Center and Professor of Medicine, Weill Cornell Medicine

Showing Events in 1 Track from 09:05am to 09:25am

New Technologies in Transformational Biology

9:05AM - 9:25AM

Beyond Cytotoxicity: Granzyme B ADCs – A New Paradigm in Immuno-Oncology Payload Discovery

Claire Thuning-Roberson, PhD, CEO, AbBC Therapies

Showing Events in 1 Track from 09:25am to 10:05am

Grand Opening of the IO360° Networking Café

9:25AM - 10:05AM

Grand Opening of the IO360° Networking Café

Showing Events in 1 Track from 10:05am to 10:45am

New Technologies in Transformational Biology (Continued)

10:05AM - 10:25AM

AstraZeneca’s Bet on In Vivo CAR-T: A Preclinical Perspective

Mark Cobbold, PhD, SVP IO and Cell Therapy Discover, AstraZeneca

10:25AM - 10:45AM

Antisense Oligonucleotides (ASOs) for Cancer: Why This Modality’s Moment Has Arrived

Zdravka Medarova, PhD, CSO & Co-founder, TransCode Therapeutics

Showing Events in 1 Track from 11:00am to 11:10am

10 Min Health Break

11:00AM - 11:10AM

10 Min Health Break

Showing Events in 1 Track from 11:10am to 12:20pm

Morning Tracks

11:10AM - 12:20PM

Two Track Choices: IO Novel Technologies Showcase

Participating Companies:

Showing Events in 2 Tracks from 12:20pm to 01:35pm

Lunch and Networking

Lunch & 1:1 Partnering Meetings Begin

Women's Luncheon

3rd Annual Women Leaders in IO Panel & Luncheon

Moderator:

Marisa Dolled-Filhart, PhD, Global Team Lead, Early Oncology; Asset and Portfolio Management, Daiichi Sankyo US

Theresa LaVallee, PhD, Chief Scientific & Development Officer, Coherus Oncology

Showing Events in 2 Tracks from 01:40pm to 03:20pm

TRACK 1: New Tech in Transformational Biology

Next-Generation Cancer Vaccines: Mining the Dark Genome for Novel Shared Antigens

Jon Moore, PhD, CSO, Epitopea

2:00PM - 2:20PM

Cytokine-Based ADCs: IL-12 and IL-18 as Immune-Modulating Payloads

2:35PM - 2:55PM

Engineering Bispecific Antibodies: Preclinical Design and Construction

2:55PM - 3:15PM

Pharma/Academia Case Study

TRACK 2: Imaging-Driven Innovation in IO

The Imaging Reality Check: Practical Insights from a Leading IO Trialist

Diwakar Davar, MD, Associate Professor, Clinical Director, Melanoma and Skin Cancer Program, UPMC Hillman Cancer Center

2:00PM - 2:40PM

Panel: Imaging Lessons from IO 1.0 to Shape IO 2.0: From Smarter Design to Meaningful Impact

David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo

2:40PM - 3:20PM

Panel: Measuring What Matters: Using Biomarkers to Guide Patient Selection and Treatment in IO

Greg Goldmacher, MD, PhD, MBA, Associate VP, Clinical Research; Head, Clinical Imaging & Pathology, Merck Research Laboratories

Catherine Hines, PhD, Executive Director and Head, Clinical Imaging, GSK

Dejan Knezevic, PhD, Senior Director, Pharma Partnerships, Natera

Showing Events in 1 Track from 03:25pm to 04:05pm

Afternoon Networking Break

3:25PM - 4:05PM

Afternoon Networking Break and Partnering Meetings

Showing Events in 2 Tracks from 04:10pm to 05:40pm

TRACK 1: Breakthroughs in Translational Science Part 1

What Drives an Effective Anti-Tumor Immune Response? Insights from Blood-Borne and Solid Tumors

Erik Manting, PhD, CEO, Mendus

4:45PM - 5:05PM

Targeting IL-27 to Activate Antitumor Immunity: Insights from Casdozokitug

Sruthi Ravindranathan, PhD, Senior Scientist, Translational Medicine, Coherus Oncology

5:20PM - 5:40PM

New Translational Insights from the VG161 Oncolytic Virotherapy Study

William Jia, PhD, CSO & Co-founder, Virogin Biotech

TRACK 2: Imaging-Driven Innovation in IO

Understanding, Detecting and Harnessing Immunogenic Cell Death in IO

Lorenzo Galluzzi, PhD, Associate Professor Cancer Signaling and Microenvironment Research Program, Fox Chase Cancer Center, Temple Health

4:30PM - 5:10PM

Panel - From Hype to Impact: Where AI in Imaging Is Moving the Needle in IO Development